JAMA Oncology Author Interviews podcast

Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer

0:00
13:01
Reculer de 15 secondes
Avancer de 15 secondes

D'autres épisodes de "JAMA Oncology Author Interviews"